Klobuch, Sebastian
Seijkens, Tom T. P.
Schumacher, Ton N. http://orcid.org/0000-0003-0517-8804
Haanen, John B. A. G. http://orcid.org/0000-0001-5884-7704
Article History
Accepted: 4 December 2023
First Online: 8 January 2024
Competing interests
: S.K. has acted as an adviser of Regeneron. T.N.S. has acted as an adviser of Allogene Therapeutics, Asher Therapeutics, Celsius, Merus, Neogene Therapeutics and Scenic Biotech; is a stockholder in Allogene Therapeutics, Asher Therapeutics, Cell Control, Celsius, Merus and Scenic Biotech; and is a venture partner at Third Rock Ventures. J.B.A.G.H. has acted as an adviser of Achilles Therapeutics, BioNTech, Bristol Myers Squibb, CureVac, Gadeta, Immunocore, Instil Bio, Iovance Bio, Ipsen, Merck Serono, Molecular Partners, MSD, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Scenic, Seattle Genetics, Third Rock Ventures and T-Knife, and has received research grants from Amgen, Asher Bio, BioNTech, Bristol Myers Squibb, MSD, Novartis and Sastra Cell Therapy. T.T.P.S. declares no competing interests.